OBJECTIVES: Currently, preimplant balloon aortic valvuloplasty (BAV) is considered a prerequisite for successful subsequent transapical transcatheter aortic valve implantation (TA-TAVI) using balloon-expandable devices. However, cerebral embolization has been shown to originate at least in part from BAV procedures. Omitting BAV may therefore reduce neurological events after TAVI and facilitate the procedure while yielding non-inferior haemodynamic and clinical outcomes. , study group) using the Edwards Sapien XT device (54% male, age 78 ± 8 years, logistic European System for Cardiac Operative Risk Evaluation I 21 ± 14%). Data were prospectively entered into a dedicated database, retrospectively analysed and compared with a consecutive series of conventional TA-TAVI using the same device (control group, n = 50). Reporting of data followed Valve Academic Research Consortium definitions.
INTRODUCTION
Transcatheter aortic valve implantation (TAVI) has been established as a routine procedure for treatment of inoperable or high-risk patients with severe aortic stenosis [1, 2] . While clinical outcomes have constantly improved with growing physician experience, technical refinement of devices and improved periprocedural care, major safety issues remain such as conduction disturbances, paravalvular leakage (PVL) or periprocedural cerebrovascular embolism.
The latter has been shown to originate from different technical steps during TAVI such as wire passage of the native aortic valve, balloon aortic valvuloplasty (BAV) or positioning and deployment of valves [3] . Reducing manipulation of the stenosed native aortic valve may therefore potentially decrease the rate of cerebrovascular events.
Performing preimplant BAV before insertion and deployment of TAVI devices is considered a mandatory step by most centres to 'pave the way' before valve implantation or it may also be used for final measurement of annular dimensions [4] . However, BAV in itself carries its own specific procedural risks [5] . In a multicentre study feasibility of transfemoral TAVI using a self-expandable device has been demonstrated [6] . Furthermore, Wendler et al. [7] recently reported their preliminary experience of TA-TAVI without BAV in a series of 6 patients using a balloon-expandable prosthesis.
In the present study, we assessed safety and feasibility of TA-TAVI −BAV using a balloon-expandable device. Clinical and haemodynamic results were analysed and compared with a consecutive series of patients undergoing conventional TA-TAVI with prior BAV using the same device.
PATIENTS AND METHODS

Patients
From May 2011 through December 2012, a total of 50 consecutive patients were treated by TA-TAVI −BAV for severe calcified aortic stenosis using the Edwards Sapien XT device. Patient selection was guided by current international recommendations [8] and patients allocated to TAVI by mutual agreement of the local heart team according to the individual patient's risk profile. For comparison to the study population, a control group of 50 consecutive patients treated at our centre by conventional TA-TAVI with prior BAV immediately before introduction of the new technique of TA-TAVI −BAV was retrieved from our dedicated hospital database. Written informed consent was obtained from all patients before the procedure.
Preprocedural planning and study procedure
All patients underwent preoperative transthoracic and transoesophageal echocardiographic screening for general evaluation of cardiac functional status. Furthermore, contrast-enhanced, electrocardiogram-gated multislice computed tomography (CT) was performed. Datasets were analyzed using the 3mensio Medical Imaging software (3mensio Medical Imaging BV, Bilthoven, Netherlands) for calculation of native aortic annulus dimensions and choice of adequately sized prostheses as well as characterization of valve morphology (e.g. degree and distribution of valvular calcification), preprocedural calculation of optimal c-arm angulation, determination of the exact thoracic access site and assessment of aortoiliac and peripheral vascular status.
All procedures were performed in a joint heart-team effort by a dedicated team of cardiologists and cardiac surgeons in a specially equipped hybrid operating theatre (OT). A readily primed heartlung machine was available in the hybrid OT for every case should haemodynamic instability require implementation of cardiopulmonary bypass.
Transapical (TA) procedures were performed under general anaesthesia. Since the thoracic access site was predictable from the preprocedural CT scans, incision size could be limited to 4-5 cm and the use of a rigid retractor avoided in many cases for decreased postoperative patient discomfort. For TA-TAVI procedures, left anterolateral minithoracotomy was followed by opening of the pericardium and placement of two felt-pledgeted prolene 2-0 sutures just above the true anatomical apex on the anterior left ventricular wall. The left ventricle was punctured and a soft guidewire inserted in Seldinger's technique under fluoroscopic control for antegrade passage of the aortic valve. Subsequently, a long straight 6-Fr sheath was advanced across the aortic valve and the soft wire exchanged for a super stiff guidewire (Amplatz super stiff, 260 cm, Boston Scientific, Natick, MA, USA) protected by a right Judgkins catheter (Cordis Johnson&Johnson, Norderstedt, Germany). Contrary to conventional procedures, for TA-TAVI −BAV , the TA delivery sheath was then directly inserted and the Edwards Sapien XT device positioned and deployed inside the native aortic valve under rapid ventricular pacing. All subsequent steps followed previously described protocols [9] .
Statistical analysis
Baseline, procedural and acute follow-up data to ≤30 days were prospectively entered into a dedicated standardized database and retrospectively analysed. Data are presented as absolute numbers and percentages for categorical variables and mean values and standard deviations for continuous variables. Dichotomous variables were compared using Fisher's exact test and continuous variables by t tests. P-values were reported without correction for multiple testing. A level of significance was set to two-tailed P < 0.05. Statistical analysis was performed using SPSS 20. Clinical end points were adjudicated in accordance with the updated standardized Valve Academic Research Consortium (VARC-2) definitions [10] .
RESULTS
Baseline demographics
A total of 50 consecutive patients (54% male, age 78 ± 8 years, logistic European System for Cardiac Operative Risk Evaluation I (logEuroSCORE I) 21 ± 14%) underwent TA-AVI −BAV for severe symptomatic aortic stenosis. All patients presented with significant comorbid conditions making them unfit for surgery as judged by an interdisciplinary heart team. In all cases, retrograde, transarterial access was deemed inadvisable due to severe aortoiliac and/or peripheral vascular atheropathy or small calibre peripheral vessels. The control group consisted of a same size group of consecutive patients treated by conventional TA-TAVI with prior BAV. Regarding baseline demographic and haemodynamic parameters as well as prevalence of relevant risk factors or the overall risk profile as captured by standard risk stratification tools no significant inter-group differences were found (Table 1) .
Procedural data
Acute procedural device success was observed in 94% (47/50) and 86% (43/50) of cases in study and control groups, respectively (P = 0.32). Reasons for failed interventions according to VARC-2 criteria in the study group were: conversion to surgical aortic valve replacement due to valve embolization in 1 patient, severe PVL due to low deployment of the first prosthesis requiring implantation of a second device as a valve-in-valve procedure in 1 patient and residual PVL grade 2 in 1 patient. In the control group, intervention was classified as unsuccessful for: implantation of a second device due to too low implantation of the first prosthesis in 1 patient, mean transvalvular gradient >20 mmHg in 2 patients and residual PVL grade 2 in 4 patients. In the study group, no further intraprocedural complications occurred. In the control group, rupture of the balloon occurred during valve deployment in 1 patient requiring retrieval of embolized balloon material from the aortic bifurcation using a snare. In another patient, mitral chordal rupture was noted with worsening of pre-existent moderate mitral regurgitation and subsequent elective percutaneous mitral valve repair by implantation of a MitraClip 6 days after the index procedure.
The procedure time was similar in the study group compared with the control group (88 ± 31 vs 91 ± 25 min, P = 0.60), while significantly less contrast was used (138 ± 68 vs 183 ± 78 ml, P < 0.01). Post-dilatation of deployed prostheses was performed in 8% (4/50) and 4% (2/50) in study and control groups, respectively, (P = 0.68) for >moderate PVL or increased transvalvular gradients. Detailed procedural data are summarized in Table 2 .
Echocardiographic outcome data
Significant improvements were observed in both groups comparing baseline and discharge transthoracic echocardiographic data. Device success according to VARC-2 definitions: absence of procedural mortality, correct positioning of a single prosthetic heart valve into the proper anatomical position, intended performance of the prosthetic heart valve (no prosthesis-patient mismatch and mean aortic valve gradient <20 mmHg or peak velocity <3 m/s and no moderate or severe prosthetic valve regurgitation).
In the study group, peak and mean transvalvular gradients decreased from 49 ± 22 and 28 ± 14 mmHg to 16 ± 7 and 8 ± 3 mmHg (both P < 0.01), while EOA increased from 0.9 ± 0.4 to 1.6 ± 0.3 cm 2 (P < 0.01). Corresponding data in the control group were: decrease of peak and mean gradients from 54 ± 28 mmHg and 31 ± 17 mmHg to 19 ± 9 and 9 ± 5 mmHg (both P < 0.01) and increase of EOA from 0.8 ± 0.2 to 1.7 ± 0.5 cm 2 (P < 0.01). Comparison of haemodynamic results between study and control groups revealed no statistically significant differences regarding peak and mean transvalvular gradients (P = 0.08 and P = 0.09) or resultant EOA (P = 0.23; Fig. 1 ).
Residual PVL grade 2 was present in 2% (1/50) and 8% (4/50) in study and control groups, respectively (P = 0.61), while PVL >grade 2 was not observed in any patient (Fig. 2) .
Clinical outcome data
All-cause mortality was 4% (2/50) and 10% (5/50) in study and control groups, respectively (P = 0.44). Mortality was classified as cardiovascular or of unknown cause in both cases in the study group and in 2 cases in the control group. Non-cardiovascular causes of death in the remaining 3 patients in the control group were: previously unknown advanced malignant disease, multiorgan failure and pneumonia following aspiration.
Periprocedural stroke occurred in 2% (1/50) and 6% (3/50, P = 0.62), respectively. Severity of stroke was classified as disabling in 1 patient in the study group and as disabling in 1 and nondisabling in 2 cases in the control group. There was 1 case of major access site complications in each group. No myocardial infarctions occurred. Composite early safety end point according to VARC-2 definitions was reached in 14% (7/50) and 24% (12/50, P = 0.31) in study and control groups, respectively. Further clinical outcome parameters are listed in Table 3 .
DISCUSSION
In the present study, we were able to demonstrate safety, feasibility and effectiveness of TA-TAVI −BAV in a routine sample population of elderly, high-risk patients undergoing TA-TAVI. Compared with a control group of patients undergoing conventional TA-TAVI with prior BAV, device success rate according to VARC-2 criteria was high at 94%. This compares favourably to results reported by others [11] [12] [13] [14] , even though most analyses to date conform to the initial VARC definitions [15] and employ various access routes and types of prostheses hampering direct comparison. These preliminary results suggest, BAV preceding TA-TAVI with balloon-expandable devices may be omitted without compromising technical success of valve deployment. Since BAV carries its own inherent procedural risks and needs to be performed under rapid ventricular pacing which in turn may lead to haemodynamic instability, especially in patients with impaired left ventricular function, TA-TAVI −BAV may result in increased overall safety of the procedure. On the other hand, it has been advocated that BAV preceding valve deployment may have strategic advantages in selected cases for example as a final confirmation of annular dimensions or to rule out coronary ostia obstruction by displacement of native aortic valve leaflets. Nowadays, many groups including our own find that proper planning of the procedure using contrast-enhanced ECG-gated multislice CT scans-if adequately reconstructed and analysed-are extremely reliable for determination of annular dimensions and other crucial anatomical characteristics such as distance of coronary ostia from the aortic annular plane or width of the aortic root, etc. Therefore, balloon sizing may prove not to be of such importance after all.
Similar to results by Wendler et al. [7] , the amount of contrast agent needed during the procedure was significantly reduced compared with the control group. Even though in 50 patients treated within this study, no statistically significant advantages were seen regarding incidence of acute renal failure, a beneficial effect of decreased amounts of contrast agent can likely be anticipated if this simplified procedure is applied in larger patient numbers. Potentially, procedure time and fluoroscopy time may also be reduced by omitting BAV even though this reduction did not reach statistical significance in our early experience.
The early safety end point as defined in the VARC-2 consensus document was reached in 14% in the study group compared with 24% in the control group (P = 0.31) with stroke rates of 2 and 6% in study and control groups, respectively (P = 0.62). Even though BAV is known to carry a risk of cerebral embolism with reported incidence ranging from 0.4 to 4% [5, [16] [17] [18] , the difference observed in our comparative study was statistically insignificant and it remains speculative if TA-TAVI −BAV will result in a meaningful reduction of cerebrovascular events if evaluated in larger patient numbers. At least theoretically, however, this appears likely to be the case.
Regarding acute haemodynamic effects, results in the study population proved non-inferior to those achieved by conventional TA-TAVI with significant reduction of peak and mean transvalvular gradients and increase in EOA in both groups and very similar values between groups for the respective parameters (Fig. 1) .
Rates of residual PVL in the study group compare favourably to other contemporary series [19, 20] with PVL grade 2 in only 1 case (2%) and no or PVL grade 1 in all other patients. It has to be noted, however, that the rate of post-dilatation of deployed prostheses was higher in the study group with 8% as opposed to 4% in the control group even though this difference was statistically not significant.
LIMITATIONS
The present study represents a retrospective, single-centre experience with limited patient numbers. Patients were not randomized to the respective treatment groups. Furthermore, patients in study and control groups were treated during different periods of time and even though analysis of baseline patient characteristics did not reveal statistically significant inter-group differences, results may have been biased by hidden confounders. Furthermore, since this is a retrospective assessment, the impact of a learning curve with the relatively young technique of TA-TAVI is likely inherent in the data presented.
CONCLUSIONS
In conclusion, preliminary experience in a limited number of patients suggests TA-TAVI −BAV using balloon-expandable devices is feasible and safe. Regarding valve function and rates of PVL, TA-TAVI −BAV proved non-inferior to conventional TA-TAVI with prior BAV. Possible advantages regarding the incidence of periprocedural cerebrovascular events will need to be investigated in larger patient numbers before general recommendations can be made.
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